<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131676</url>
  </required_header>
  <id_info>
    <org_study_id>1245.25</org_study_id>
    <secondary_id>2009-016178-33</secondary_id>
    <nct_id>NCT01131676</nct_id>
  </id_info>
  <brief_title>BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).</brief_title>
  <official_title>A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate the safety of BI 10773 treatment in patients
      with Type 2 Diabetes Mellitus and high cardiovascular risk.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.</measure>
    <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
    <description>Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), and non-fatal stroke.
Percentage of patients with the event are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris</measure>
    <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
    <description>The composite of all events adjudicated (4-point MACE): cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction (excluding silent MI), non-fatal stroke and hospitalization for unstable angina pectoris.This is a key secondary endpoint of the trial.
Percentage of patients with the event are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Silent MI</measure>
    <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
    <description>Silent MI; defined as presence in the ECG of:
Any Q-wave in leads V2-V3 ≥0.02 seconds or QS complex in leads V2 and V3
Q-wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF)
R-wave ≥0.04 seconds in V1-V2 and R/S ≥1 with a concordant positive T-wave in the absence of a conduction defect.
It was also required that there had been no adjudicated and confirmed event of either acute MI, hospitalisation for unstable angina, coronary revascularisation procedures or stent thrombosis following randomisation up to and including the date of the specified ECG measurement.
Percentage of patients with the event are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated)</measure>
    <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
    <description>Heart failure requiring hospitalisation (adjudicated). Percentage of patients with the event are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Onset Albuminuria</measure>
    <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
    <description>New onset albuminuria defined as urine albumin / creatinine ratio (UACR) ≥30 mg/g.
Percentage of patients with the event are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Onset Macroalbuminuria</measure>
    <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
    <description>New onset macroalbuminuria defined as UACR &gt;300 mg/g. Percentage of patients with the event are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Composite Microvascular Outcome</measure>
    <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
    <description>Composite microvascular outcome defined as:
Initiation of retinal photocoagulation
Vitreous haemorrhage
Diabetes-related blindness, or
New or worsening nephropathy defined as:
New onset of macroalbuminuria; or
Doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) ≤45 mL/min/1.73m2; or
Initiation of continuous renal replacement therapy, or
Death due to renal disease. Percentage of patients with the event are presented.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7064</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 10773</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 low dose</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BI 10773 high dose</intervention_name>
    <description>Placebo tablets identical to BI 10773</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 high dose</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BI 10773 low dose</intervention_name>
    <description>Placebo tablets identical to BI 10773</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BI 10773 low dose</intervention_name>
    <description>Placebo tablets identical to BI 10773</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BI 10773 high dose</intervention_name>
    <description>Placebo tablets identical to BI 10773</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus prior to informed consent

          2. Male or female patients on diet and exercise regimen who are drug naive or pre treated
             with any background therapy. Antidiabetic therapy has to be unchanged for 12 weeks
             prior to randomization.

          3. Glycosylated haemoglobin (HbA1c) of &gt;= 7.0% and &lt;=10% for patients on background
             therapy or HbA1c &gt;= 7.0% and &lt;= 9.0% for drug naive patients

          4. Age &gt;= 18 years

          5. Body Mass index &lt;= 45 at Visit 1

          6. Signed and dated informed consent

          7. High cardiovascular risk

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an
             overnight fast during placebo run-in and confirmed by a second measurement (not on the
             same day)

          2. Indication of liver disease, defined by serum levels of either alanine
             aminotransferase (ALT), aspartate aminotransferase ALT or alkaline phosphatase above 3
             x upper limit of normal (ULN) as determined at screening and/or run in.

          3. Planned cardiac surgery or angioplasty within 3 months

          4. Impaired renal function, defined as Glomerular Filtration Rate &lt;30 ml/min (severe
             renal impairment, Modification of Diet in Renal Disease formula) during screening or
             run in.

          5. Bariatric surgery within the past two years and other gastrointestinal surgeries that
             induce chronic malabsorption

          6. Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g.
             malaria, babesiosis, haemolytic anemia)

          7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for
             cancer within the last 5 years

          8. Contraindications to background therapy according to the local label

          9. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to
             informed consent or any other treatment at the time of screening (i.e. surgery,
             aggressive diet regimen, etc.) leading to unstable body weight

         10. Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent or any other
             uncontrolled endocrine disorder except type 2 diabetes mellitus

         11. Pre-menopausal women (last menstruation &lt;+ 1 year prior to informed consent) who:

               -  are nursing or pregnant or

               -  are of child-bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the study
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include tubal ligation,
                  transdermal patch, intra uterine devices/systems, oral, implantable or injectable
                  contraceptives, sexual abstinence, double barrier method and vasectomised partner

         12. Alcohol or drug abuse within the 3 months prior to informed consent that would
             interfere with trial participation or any ongoing condition leading to a decreased
             compliance to study procedures or study drug intake

         13. Participation in another trial with an investigational drug within 30 days prior to
             informed consent

         14. Any other clinical condition that would jeopardize patients safety while participating
             in this clinical trial

         15. Acute coronary syndrome, stroke or TIA within 2 months prior to informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.25.10043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10175 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10158 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harbor City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10193 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10094 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10190 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10212 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10200 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10168 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10184 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10147 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10198 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10178 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10211 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10174 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10092 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10097 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10186 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10176 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10163 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10148 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10191 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10180 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10096 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10196 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calabash</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10138 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10156 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10192 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clairton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10173 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clairton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Feasterville Trevose</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10172 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greensburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10214 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10197 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10162 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hodges</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10170 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10171 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10165 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10169 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10189 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10160 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10177 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10161 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10185 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10218 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Chesterfield</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10216 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10187 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10182 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.10098 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parque Velez Sarfield</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.54009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ashford</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fullarton</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Stefan</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.43013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>De Pinte</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huy</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Massemen-Wetteren</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.32014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oostham</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belém</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boqueirão</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasília</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higienópolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maringá</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ribeirão Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São José do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Albuquerque</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Clementino</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Leopoldina</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villa Clementino</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.20041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.57010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.57004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.57001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.57003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.57011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.57006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.57009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.71005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.71001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krapinske Toplice</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.71006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.71003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.71002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.71004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.42020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.42018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.42015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 3</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.42019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsingør</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Randers NØ</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.37005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.37004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg des cptes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Derval</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Equeurdreville Haineville</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fleury sur Orne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Creusot</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Narbonne Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Priez en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.33035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kutaisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.99008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nikaia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.30008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.85201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.85205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.85207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.85208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunaujvaros</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kisvarda</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.36011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szikszo</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91317 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91319 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91320 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91315 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cochin</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91318 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jalandhar</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91313 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91324 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashik, Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91316 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Secunderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91321 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varanasi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.91314 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vijaywada</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denpasar, Bali</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Depok</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malang</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Surabaya</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.62001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.97003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.97006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.97008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.97009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.97005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.97001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.97002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.39013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Venezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifushi, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanyushi, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamigyo-ku, Kyotoshi, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwadashi. Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Nagoyashi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto-shi, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsudoshi, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mitoshi, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Sapporoshi, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nodashi, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimajiri-gun,Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyamashi, Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyoakeshi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejoen</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.82028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kedah</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kota Kinabalu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pahang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor Darul Ehsan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.60021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.52009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colonia Americana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.52007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.52013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ladron de Guevara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.52010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Robles</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.52011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reforma Social</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.52012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Lucas tepetlcalco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baarle - Nassau</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Helder</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hardenberg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogeveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogezand</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogwoud</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meppel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijverdal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wildervank</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.31034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.64004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grafton / Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fornebu</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gjøvik</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kløfta</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kongsvinger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tynset</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellavista</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>El Agustino</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ica</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jesus Maria</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.51005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miraflores</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cavite City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Davao</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaro Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marikina City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marikina City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.63019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarlac</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pulawy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.48011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Faro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Funchal</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiria</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago do Cacém</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torres Novas</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Viana do Castelo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.35019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alba Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baia Mare Maramures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.40010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.70029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.65001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.65003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.65004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alberton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chatsworth Unit 10</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goodwood</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houghton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kempton Park</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newtown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paarl</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parow</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sydenham</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tongaat</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.76023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Worcester</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alcorcon (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alzira</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Avila</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badía del Vallès - Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leganes (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mahadahonda (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.34046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.94002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.94005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalubowila</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.94004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kandy</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.94006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kandy</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.94001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nugegoda</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.94003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ragama</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tamsui, Taipei county</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.88017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.66006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.66007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.66009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.66004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muang District</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.66010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakhonratchasima</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.66011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pathum Tani</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.75009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.75011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.75001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.75008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.75007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.75012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.75010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Airdrie</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ashford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dumfries</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fowey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frome</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.25.44044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wishaw</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sri Lanka</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>El Salvador</country>
    <country>Germany</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Saudi Arabia</country>
    <country>Switzerland</country>
    <country>United Arab Emirates</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <results_first_submitted>April 7, 2016</results_first_submitted>
  <results_first_submitted_qc>April 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients randomised to treatments in 1:1:1 ratio.</recruitment_details>
      <pre_assignment_details>Randomisation stratified by:BMI at randomisation(&lt;30/≥30 kg/m2),HbA1c at screening (&lt;8.5%/ ≥8.5%);geographical region(North America including Australia and New Zealand,Latin America,Europe,Africa,Asia);renal function at screening (normal:eGFR ≥90 mL/min, mild impairment:60 mL/min ≤ eGFR ≤89 mL/min, moderate impairment:30 mL/min ≤ eGFR≤59 mL/min).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 10 mg</title>
          <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 25 mg</title>
          <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Discontinuation From Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2337">Randomised</participants>
                <participants group_id="P2" count="2347">Randomised</participants>
                <participants group_id="P3" count="2344">Randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1650">Not prematurely discontinued from trial medication</participants>
                <participants group_id="P2" count="1790">Not prematurely discontinued from trial medication</participants>
                <participants group_id="P3" count="1800">Not prematurely discontinued from trial medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="687"/>
                <participants group_id="P2" count="557"/>
                <participants group_id="P3" count="544"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study drug stopped, reason missing</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal to continue, not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="122"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than those specified</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="125"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="267"/>
                <participants group_id="P3" count="273"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Discontinuation From Study (Treated Set)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2333"/>
                <participants group_id="P2" count="2345"/>
                <participants group_id="P3" count="2342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Final Vital Status (VS) Available</title>
              <participants_list>
                <participants group_id="P1" count="2316"/>
                <participants group_id="P2" count="2324"/>
                <participants group_id="P3" count="2327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2266">Completed the trial or died</participants>
                <participants group_id="P2" count="2264">Completed the trial or died</participants>
                <participants group_id="P3" count="2279">Completed the trial or died</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent withdrawn: Final VS available</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn:Final VS not available</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closure: Final VS available</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closure:Final VS not available (NA)</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to FU for 3PMACE:Final VS available</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to FU for 3P-MACE:Final VS NA</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): Consists of all randomised patients who received at least 1 dose of study medication. Patients were assigned to treatment groups according to the randomisation scheme.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 10 mg</title>
          <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 25 mg</title>
          <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2333"/>
            <count group_id="B2" value="2345"/>
            <count group_id="B3" value="2342"/>
            <count group_id="B4" value="7020"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="8.8"/>
                    <measurement group_id="B2" value="63.0" spread="8.6"/>
                    <measurement group_id="B3" value="63.2" spread="8.6"/>
                    <measurement group_id="B4" value="63.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="653"/>
                    <measurement group_id="B2" value="692"/>
                    <measurement group_id="B3" value="659"/>
                    <measurement group_id="B4" value="2004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1680"/>
                    <measurement group_id="B2" value="1653"/>
                    <measurement group_id="B3" value="1683"/>
                    <measurement group_id="B4" value="5016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.</title>
        <description>Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), and non-fatal stroke.
Percentage of patients with the event are presented.</description>
        <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O4">
            <title>All Empagliflozin</title>
            <description>Patients who received either 10 mg or 25 mg of empagliflozin were pooled into a common empagliflozin treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.</title>
          <description>Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), and non-fatal stroke.
Percentage of patients with the event are presented.</description>
          <population>TS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2333"/>
                <count group_id="O2" value="2345"/>
                <count group_id="O3" value="2342"/>
                <count group_id="O4" value="4687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Primary objective was to establish the non-inferiority of All empagliflozin relative to placebo for time to first 3-point MACE. A 4-step hierarchical testing strategy was followed for the non-inferiority test of the primary endpoint and then the key secondary endpoint, each at a margin of 1.3, followed by test of superiority of primary and key secondary endpoints.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was chosen as 1.3 based on Food and Drug Administration (FDA) Guidance for Industry – Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided test with alpha = 0.0249</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95.02</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0382</p_value>
            <p_value_desc>Two-sided test with alpha=0.0498</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95.02</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris</title>
        <description>The composite of all events adjudicated (4-point MACE): cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction (excluding silent MI), non-fatal stroke and hospitalization for unstable angina pectoris.This is a key secondary endpoint of the trial.
Percentage of patients with the event are presented.</description>
        <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O4">
            <title>All Empagliflozin</title>
            <description>Patients who received either 10 mg or 25 mg of empagliflozin were pooled into a common empagliflozin treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris</title>
          <description>The composite of all events adjudicated (4-point MACE): cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction (excluding silent MI), non-fatal stroke and hospitalization for unstable angina pectoris.This is a key secondary endpoint of the trial.
Percentage of patients with the event are presented.</description>
          <population>TS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2333"/>
                <count group_id="O2" value="2345"/>
                <count group_id="O3" value="2342"/>
                <count group_id="O4" value="4687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="12.8"/>
                    <measurement group_id="O3" value="12.8"/>
                    <measurement group_id="O4" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A 4-step hierarchical testing strategy was followed for the non-inferiority test of the primary endpoint and then the key secondary endpoint, each at a margin of 1.3, followed by test of superiority of primary and key secondary endpoints.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was chosen as 1.3 based on Food and Drug Administration (FDA) Guidance for Industry – Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided test with alpha = 0.0249</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95.02</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A 4-step hierarchical testing strategy was followed for the non-inferiority test of the primary endpoint and then the key secondary endpoint, each at a margin of 1.3, followed by test of superiority of primary and key secondary endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0795</p_value>
            <p_value_desc>Two-sided test with alpha=0.0498</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95.02</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Silent MI</title>
        <description>Silent MI; defined as presence in the ECG of:
Any Q-wave in leads V2-V3 ≥0.02 seconds or QS complex in leads V2 and V3
Q-wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF)
R-wave ≥0.04 seconds in V1-V2 and R/S ≥1 with a concordant positive T-wave in the absence of a conduction defect.
It was also required that there had been no adjudicated and confirmed event of either acute MI, hospitalisation for unstable angina, coronary revascularisation procedures or stent thrombosis following randomisation up to and including the date of the specified ECG measurement.
Percentage of patients with the event are presented.</description>
        <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
        <population>TS (evaluable cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O4">
            <title>All Empagliflozin</title>
            <description>Patients who received either 10 mg or 25 mg of empagliflozin were pooled into a common empagliflozin treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Silent MI</title>
          <description>Silent MI; defined as presence in the ECG of:
Any Q-wave in leads V2-V3 ≥0.02 seconds or QS complex in leads V2 and V3
Q-wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF)
R-wave ≥0.04 seconds in V1-V2 and R/S ≥1 with a concordant positive T-wave in the absence of a conduction defect.
It was also required that there had been no adjudicated and confirmed event of either acute MI, hospitalisation for unstable angina, coronary revascularisation procedures or stent thrombosis following randomisation up to and including the date of the specified ECG measurement.
Percentage of patients with the event are presented.</description>
          <population>TS (evaluable cases)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1211"/>
                <count group_id="O2" value="1174"/>
                <count group_id="O3" value="1204"/>
                <count group_id="O4" value="2378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4172</p_value>
            <p_value_desc>Two-sided test with alpha = 0.05.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated)</title>
        <description>Heart failure requiring hospitalisation (adjudicated). Percentage of patients with the event are presented.</description>
        <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O4">
            <title>All Empagliflozin</title>
            <description>Patients who received either 10 mg or 25 mg of empagliflozin were pooled into a common empagliflozin treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated)</title>
          <description>Heart failure requiring hospitalisation (adjudicated). Percentage of patients with the event are presented.</description>
          <population>TS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2333"/>
                <count group_id="O2" value="2345"/>
                <count group_id="O3" value="2342"/>
                <count group_id="O4" value="4687"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <p_value_desc>Two-sided test with alpha = 0.05.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Onset Albuminuria</title>
        <description>New onset albuminuria defined as urine albumin / creatinine ratio (UACR) ≥30 mg/g.
Percentage of patients with the event are presented.</description>
        <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
        <population>TS (evaluable cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O4">
            <title>All Empagliflozin</title>
            <description>Patients who received either 10 mg or 25 mg of empagliflozin were pooled into a common empagliflozin treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Onset Albuminuria</title>
          <description>New onset albuminuria defined as urine albumin / creatinine ratio (UACR) ≥30 mg/g.
Percentage of patients with the event are presented.</description>
          <population>TS (evaluable cases)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1374"/>
                <count group_id="O2" value="1403"/>
                <count group_id="O3" value="1376"/>
                <count group_id="O4" value="2779"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="51.5"/>
                    <measurement group_id="O3" value="51.5"/>
                    <measurement group_id="O4" value="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2547</p_value>
            <p_value_desc>Two-sided test with alpha = 0.05.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Onset Macroalbuminuria</title>
        <description>New onset macroalbuminuria defined as UACR &gt;300 mg/g. Percentage of patients with the event are presented.</description>
        <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
        <population>TS (evaluable cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O4">
            <title>All Empagliflozin</title>
            <description>Patients who received either 10 mg or 25 mg of empagliflozin were pooled into a common empagliflozin treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Onset Macroalbuminuria</title>
          <description>New onset macroalbuminuria defined as UACR &gt;300 mg/g. Percentage of patients with the event are presented.</description>
          <population>TS (evaluable cases)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2033"/>
                <count group_id="O2" value="2037"/>
                <count group_id="O3" value="2054"/>
                <count group_id="O4" value="4091"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="11.5"/>
                    <measurement group_id="O4" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided test with alpha = 0.05.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Composite Microvascular Outcome</title>
        <description>Composite microvascular outcome defined as:
Initiation of retinal photocoagulation
Vitreous haemorrhage
Diabetes-related blindness, or
New or worsening nephropathy defined as:
New onset of macroalbuminuria; or
Doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) ≤45 mL/min/1.73m2; or
Initiation of continuous renal replacement therapy, or
Death due to renal disease. Percentage of patients with the event are presented.</description>
        <time_frame>From randomisation to individual end of observation, up to 4.6 years</time_frame>
        <population>TS (evaluable cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
          </group>
          <group group_id="O4">
            <title>All Empagliflozin</title>
            <description>Patients who received either 10 mg or 25 mg of empagliflozin were pooled into a common empagliflozin treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Composite Microvascular Outcome</title>
          <description>Composite microvascular outcome defined as:
Initiation of retinal photocoagulation
Vitreous haemorrhage
Diabetes-related blindness, or
New or worsening nephropathy defined as:
New onset of macroalbuminuria; or
Doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) ≤45 mL/min/1.73m2; or
Initiation of continuous renal replacement therapy, or
Death due to renal disease. Percentage of patients with the event are presented.</description>
          <population>TS (evaluable cases)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2068"/>
                <count group_id="O2" value="2057"/>
                <count group_id="O3" value="2075"/>
                <count group_id="O4" value="4132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="13.9"/>
                    <measurement group_id="O3" value="14.1"/>
                    <measurement group_id="O4" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided test with alpha = 0.05.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <method_desc>Cox proportional hazards model with factors for treatment, age, gender, categorised BMI, HbA1c, eGFR and geographical region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
            <estimate_desc>All Empagliflozin divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs, serious and non-serious, occurring during the course of the clinical trial (from randomisation through the follow-up period); up to 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 10 mg</title>
          <description>Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 25 mg</title>
          <description>Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="988" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="876" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="913" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypereosinophilic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bundle branch block bilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac failure high output</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Papillary muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pericardial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Congenital anomalies of ear ossicles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Corneal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Exfoliation syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Retinoschisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vitreous opacities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bezoar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colon dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Stress ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Device defective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Device deposit issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Device difficult to use</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Implant site necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Necrobiosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oversensing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pacemaker generated arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Stent malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Post cholecystectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sphincter of Oddi dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Iodine allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Abscess of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cutaneous larva migrans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal protozoal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Infusion site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Inguinal hernia gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intestinal fistula infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intestinal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Meningitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vaginal cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Periorbital contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Traumatic renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Angiogram normal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Biopsy lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood pressure orthostatic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oxygen consumption increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Physical examination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Scan myocardial perfusion abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Insulin resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lipomatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bone fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dactylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fracture delayed union</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gouty tophus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lower extremity mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteitis deformans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign respiratory tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Benign uterine neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bone giant cell tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Genital neoplasm malignant female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemangioma of bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Large cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lymphocytic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastases to neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>POEMS syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Papillary serous endometrial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Penile squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Salivary gland adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Splenic marginal zone lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Autonomic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Brain stem ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Central nervous system inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebral ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypercapnic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Mononeuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Piriformis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spinal epidural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vertebral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vocal cord paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Rapid eye movements sleep abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bladder neck sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cystitis glandularis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lower urinary tract symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Mediastinal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pulmonary toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vocal cord thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic bullosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Neuropathic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Skin fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Skin ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Fracture treatment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diabetic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Femoral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vascular calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1690" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="1556" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="1551" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="149" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="220" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="344" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="339" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="337" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="423" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="202" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="685" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="694" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="673" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="173" subjects_at_risk="2342"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="2333"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="2345"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="2342"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>2 sets of duplicates(4 patients(pts)) were counted only once.652 sites were initiated and 611 enrolled.One site transferred all pts to other sites.27 pts randomised and 13 pts screened were excluded from analyses due to serious non-compliance</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>800-243-0127 ext +1</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

